- Home
- HUM vs ROIV Comparison
HUM vs ROIV Comparison
Compare HUM & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HUM | ROIV |
|---|---|---|
| Founded | 1961 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.5B | 20.7B |
| IPO Year | 2002 | 2021 |
Fundamental Metrics
Financial Performance| Metric | HUM | ROIV |
|---|---|---|
| Price | $214.13 | $27.08 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 20 | 9 |
| Target Price | ★ $238.65 | $28.94 |
| AVG Volume (30 Days) | 1.5M | ★ 4.5M |
| Earning Date | 04-29-2026 | 05-28-2026 |
| Dividend Yield | ★ 1.65% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 9.84 | N/A |
| Revenue | ★ $129,664,000,000.00 | $29,053,000.00 |
| Revenue This Year | $26.15 | N/A |
| Revenue Next Year | $6.07 | $744.61 |
| P/E Ratio | $21.71 | ★ N/A |
| Revenue Growth | ★ 10.11 | N/A |
| 52 Week Low | $163.11 | $10.58 |
| 52 Week High | $315.35 | $30.33 |
Technical Indicators
Market Signals| Indicator | HUM | ROIV |
|---|---|---|
| Relative Strength Index (RSI) | 70.89 | 43.41 |
| Support Level | $206.87 | $26.94 |
| Resistance Level | $285.02 | $27.94 |
| Average True Range (ATR) | 6.73 | 0.85 |
| MACD | 2.56 | -0.12 |
| Stochastic Oscillator | 74.14 | 14.42 |
Price Performance
Historical ComparisonAbout HUM Humana Inc.
Humana is one of the largest private health insurers in the US, and the firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from Medicare, Medicaid, and the military's Tricare program. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.